Genetic Analysis of Hereditary Prostate Cancer
Launched by NATIONAL HUMAN GENOME RESEARCH INSTITUTE (NHGRI) · Nov 3, 1999
Trial Information
Current as of March 21, 2025
Completed
Keywords
ClinConnect Summary
Molecular approaches to the understanding of human neoplastic disease have revealed that multiple genetic alterations are an essential component of tumorigenesis. Both germline and somatic genetic alterations can be involved in the malignant transformation of normal cells. Identification of the genes involved in neoplastic transformation has been approached through the molecular analysis of sporadic cancers and the genetic study of families with an inherited predisposition for cancer. The interplay of these two approaches has led to the characterization of genes such as the retinoblastoma (...
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- Enrollment in this study includes case-control data from men with prostate cancer and matched controls who are free from the disease, plus affected and unaffected individuals from families who meet the following criteria for Hereditary Prostate Cancer:
- • 1. A cluster of 3 or more first degree relatives, such as a father and 2 sons or 3 brothers
- • 2. The occurrence of prostate cancer in each of 3 generations in either the proband's paternal or maternal lineages
- • 3. Two first or second-degree relatives affected at an early age (age 55 years or younger).
Trial Officials
Joan Bailey-Wilson, Ph.D.
Principal Investigator
National Human Genome Research Institute (NHGRI)
About National Human Genome Research Institute (Nhgri)
The National Human Genome Research Institute (NHGRI) is a prominent research organization within the National Institutes of Health (NIH) dedicated to advancing the field of genomics and its applications in health and medicine. NHGRI sponsors and conducts a wide range of clinical trials aimed at understanding the genetic basis of diseases, developing innovative genomic technologies, and translating genomic research into clinical practice. With a commitment to ethical research and collaboration, NHGRI plays a pivotal role in shaping the future of personalized medicine and improving patient outcomes through genomic discoveries.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bronx, New York, United States
Bethesda, Maryland, United States
Phoenix, Arizona, United States
Washington, District Of Columbia, United States
New Orleans, Louisiana, United States
Baltimore, Maryland, United States
Winston Salem, North Carolina, United States
Tampere, , Finland
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials